Patents Assigned to Pfizer Inc.
  • Publication number: 20200069764
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.
    Type: Application
    Filed: November 19, 2019
    Publication date: March 5, 2020
    Applicant: Pfizer Inc.
    Inventors: Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
  • Publication number: 20200071306
    Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
    Type: Application
    Filed: August 28, 2019
    Publication date: March 5, 2020
    Applicant: Pfizer Inc.
    Inventors: William Paul Esler, Trenton Thomas Ross
  • Patent number: 10570189
    Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: February 25, 2020
    Assignee: PFIZER INC.
    Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
  • Patent number: 10570121
    Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: February 25, 2020
    Assignee: Pfizer Inc.
    Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
  • Patent number: 10570202
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 25, 2020
    Assignees: Pfizer Inc., Merck Sharpe & Dohme Corp.
    Inventors: Jean-Francois Andre Martini, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
  • Publication number: 20200054628
    Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 10 to about 70 weight percent of biocompatible polymers such as a di-block polymer (for example, poly(lactic)acid and polyethylene glycol or poly(lactic)-co-poly (glycolic) acid and poly(ethylene)glycol), about 5 to about 50 weight percent glyceride (for example, a monoglyceride, a diglyceride, or a triglyceride), and about 0.1% to about 40% weight percent therapeutic agent (for example, docetaxel or bortezomib).
    Type: Application
    Filed: October 17, 2017
    Publication date: February 20, 2020
    Applicant: Pfizer Inc.
    Inventor: Young-Ho Song
  • Publication number: 20200054598
    Abstract: The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 20, 2020
    Applicants: Merck Sharp & Dohme Corp., Pfizer Inc.
    Inventors: Ramachandra G. Naik, Elizabeth S. Ommen, James Michael Rusnak, Steven G. Terra
  • Publication number: 20200056190
    Abstract: Provided herein is a tyrosine selection marker system, and uses thereof. In some embodiments, nucleic acid constructs, vectors, host cells and related compositions and methods for generating and selecting tyrosine prototroph cells are provided.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 20, 2020
    Applicant: PFIZER INC.
    Inventors: Gregory Walter HILLER, Jeffrey Joseph MITCHELL, Bhanu Chandra MULUKUTLA, Pamela Mary PEGMAN
  • Publication number: 20200038368
    Abstract: The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 6, 2020
    Applicants: Merck Sharp & Dohme Corp., Pfizer Inc.
    Inventors: Brett Lauring, Samuel S. Engel, Steven G. Terra, James M. Rusnak
  • Publication number: 20200039960
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 6, 2020
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, Jr., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Publication number: 20200038409
    Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.
    Type: Application
    Filed: September 24, 2019
    Publication date: February 6, 2020
    Applicant: Pfizer Inc.
    Inventors: Andrew FENSOME, Ariamala GOPALSAMY, Brian S. GERSTENBERGER, Ivan Viktorovich EFREMOV, Zhao-Kui WAN, Betsy PIERCE, Jean-Baptiste TELLIEZ, John I. TRUJILLO, Liying ZHANG, Li XING, Eddine SAIAH
  • Patent number: 10550159
    Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: February 4, 2020
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark E. Ruppen
  • Patent number: 10550200
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: February 4, 2020
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Patent number: 10543267
    Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: January 28, 2020
    Assignee: Pfizer Inc.
    Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Judith Absalon, Jose Miguel Aste-Amezaga, Johannes Frederik Beeslaar, David Cooper, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Thomas Richard Jones, Isis Kanevsky, Lakshmi Khandke, Paul Liberator, John Lance Perez, Lynn Marie Phelan, Gary Warren Zlotnick
  • Patent number: 10544095
    Abstract: A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: January 28, 2020
    Assignees: Pfizer Inc., iTeos Therapeutics
    Inventors: Sacha Ninkovic, Michael Raymond Collins, Stefano Crosignani, Andreas Maderna, Indrawan James McAlpine, Stephanie Anne Scales, Martin Wythes
  • Patent number: 10544395
    Abstract: A method of cell culture comprising providing cells in a cell culture medium to start a cell culture process, and, maintaining at least one metabolite selected from 3-(4-hydroxyphenyl)lactate, 4-hydroxyphenylpyruvate, phenyllactate, indolelactate, indolecarboxylic acid, homocysteine, 2-hydroxybutyric acid, isovalerate and formate below a concentration C1 in the cell culture medium, wherein C1 is 3 mM and/or (ii) maintaining at least one amino acid selected from phenylalanine, tyrosine, tryptophan, methionine, leucine, serine, threonine and glycine below a concentration C2 in the cell culture medium, wherein C2 is 2 mM.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: January 28, 2020
    Assignee: Pfizer Inc.
    Inventors: Gregory Walter Hiller, Bhanu Chandra Mulukutla
  • Patent number: 10544212
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: January 28, 2020
    Assignee: Pfizer Inc.
    Inventors: Laird Bloom, Karl Henry Nocka, James Reasoner Apgar, Matthew Allister Lambert, Mark A. Farmer
  • Patent number: 10538542
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: January 21, 2020
    Assignee: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Publication number: 20200010566
    Abstract: The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.
    Type: Application
    Filed: May 21, 2019
    Publication date: January 9, 2020
    Applicant: Pfizer Inc.
    Inventors: Chew Shun Chang, Gurkan Guntas, Madan Katragadda, Divya Mathur, Adam Reid Root, Lidia Mosyak, Edward Roland LaVallie
  • Publication number: 20190387710
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla